Partner with Us
The ATG Project has an extensive and growing portfolio of innovative gene therapy technologies for therapeutic advancement in rare and ultra-genetic disease. If you are a patient family, foundation or company interested in accessing these next generation technologies, the ATG Project wants to work with you.
Ongoing gene therapy collaboration for ANT1 Cardiomyopathy
Internal ANT1 cardiomyopathy program for SLC25A4 deficiency
Adenine nucleotide translocase 1 (ANT1) deficiency leads to dysfunctional energy production in heart and muscle cells. Patients with this disease have severe exercise intolerance due to hypertrophic cardiomyopathy and skeletal myopathy. We are working on a gene replacement strategy to restore ANT1 levels and provide a disease-modifying therapeutic option for these patients.
Patients, Families and Foundations
If you are interested in accessing technology in the ATG Project portfolio to develop next generation therapeutics for your community, please contact us!
Industry
If you are a for profit industry partner and interested in accessing the ATG Project's extensive portfolio, contact us below!
CDMOs
If you are a CDMO, interested in becoming part of the ATG Project service provider network to lower the barrier of entry, please contact us!